Literature DB >> 22268312

Neurological complications in HIV.

Celia Hogan1, Ed Wilkins.   

Abstract

HIV is neuroinvasive with early involvement of the nervous system and has the potential to cause disease at any site of the neuro-axis during the evolution from seroconversion to late stage HIV. Disease may result from direct viral infection, indirect immune-deficiency driven opportunistic infections, AIDS-defining cancers, antiretroviral (ARV) drug therapy, or less well elucidated associations, such as vascular events (Table 1). Recognition of each of these is paramount in the prevention or attenuation of long-term morbidity. Though the epidemiology of neurological disease has altered substantially since the arrival of combination antiretroviral therapy (cART), with reduced incidence and improved survival, the spectrum of central nervous system (CNS) diseases has remained relatively unchanged. Despite available treatment options, mortality remains high and the morbidity significant. CNS diseases can result in long hospital stays, reduced quality of life and marked disability. The majority of disease occurs in the advanced stages of HIV infection where immunosuppression is the predominant influence. Diagnosis can prove challenging as presentation is often atypical and there can be significant neurological involvement with limited evidence of disease. Multiple aetiologies can co-exist and investigations may yield unexpected results, rendering interpretation difficult. Paradoxically, cART may also alter the way CNS disease manifests and unmask opportunistic infections or cause clinical representation of the opportunistic infections, when it represents immune reconstitution syndrome (IRS). Clinical assessment, imaging (typically magnetic resonance imaging (MRI)) and cerebral spinal fluid (CSF) sampling remain the chief diagnostic tools. This conference summary reviews these differing aspects.

Entities:  

Mesh:

Year:  2011        PMID: 22268312      PMCID: PMC4952339          DOI: 10.7861/clinmedicine.11-6-571

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


  14 in total

Review 1.  Update on HIV-associated neurocognitive disorders.

Authors:  Tariq B Alfahad; Avindra Nath
Journal:  Curr Neurol Neurosci Rep       Date:  2013-10       Impact factor: 5.081

Review 2.  Neuroimmunology of CNS HIV Infection: A Narrative Review.

Authors:  Ana-Claire Meyer; Alfred Kongnyu Njamnshi; Magnus Gisslen; Richard W Price
Journal:  Front Neurol       Date:  2022-06-14       Impact factor: 4.086

Review 3.  HIV-1 Nef in macrophage-mediated disease pathogenesis.

Authors:  Susanna L Lamers; Gary B Fogel; Elyse J Singer; Marco Salemi; David J Nolan; Leanne C Huysentruyt; Michael S McGrath
Journal:  Int Rev Immunol       Date:  2012-12       Impact factor: 5.311

4.  Peripheral neuropathy in primary HIV infection associates with systemic and central nervous system immune activation.

Authors:  Samantha X Y Wang; Emily L Ho; Marie Grill; Evelyn Lee; Julia Peterson; Kevin Robertson; Dietmar Fuchs; Elizabeth Sinclair; Richard W Price; Serena Spudich
Journal:  J Acquir Immune Defic Syndr       Date:  2014-07-01       Impact factor: 3.731

5.  Neurological Complications in Controlled HIV Infection.

Authors:  Kate M Crossley; Bruce J Brew
Journal:  Curr Infect Dis Rep       Date:  2013-12       Impact factor: 3.725

6.  Transmigration of Tetraspanin 2 (Tspan2) siRNA Via Microglia Derived Exosomes across the Blood Brain Barrier Modifies the Production of Immune Mediators by Microglia Cells.

Authors:  Jessica L Reynolds; Supriya D Mahajan
Journal:  J Neuroimmune Pharmacol       Date:  2019-12-10       Impact factor: 4.147

7.  A Case of HIV Seroconversion Presenting Similarly to Anti-N-methyl-D-aspartate Receptor Encephalitis.

Authors:  Heather VanDongen-Trimmer; Kumar Sannagowdara; Binod Balakrishnan; Raquel Farias-Moeller
Journal:  Neurocrit Care       Date:  2019-10       Impact factor: 3.532

8.  Persistent metabolic changes in HIV-infected patients during the first year of combination antiretroviral therapy.

Authors:  N Chantal Peltenburg; Johannes C Schoeman; Jun Hou; Fernando Mora; Amy C Harms; Selwyn H Lowe; Jörgen Bierau; Jaap A Bakker; Annelies Verbon; Thomas Hankemeier; Andre Boonstra
Journal:  Sci Rep       Date:  2018-11-16       Impact factor: 4.379

9.  Persistence of viral reservoirs in multiple tissues after antiretroviral therapy suppression in a macaque RT-SHIV model.

Authors:  Christopher Kline; Jean Ndjomou; Tamera Franks; Rebecca Kiser; Vicky Coalter; Jeremy Smedley; Michael Piatak; John W Mellors; Jeffrey D Lifson; Zandrea Ambrose
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240

10.  Glycoproteomic analysis identifies human glycoproteins secreted from HIV latently infected T cells and reveals their presence in HIV+ plasma.

Authors:  Weiming Yang; Jian-Ying Zhou; Li Chen; Minghui Ao; Shisheng Sun; Paul Aiyetan; Antoine Simmons; Hui Zhang; Jay Brooks Jackson
Journal:  Clin Proteomics       Date:  2014-03-06       Impact factor: 3.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.